If the patient is already treated with open label vasopressors at baseline, the blinded solution will be rapidly incremented, and, if possible, the open label vasopressor agent will be decreased. If this open label vasopressor consisted in dopamine and if this agent cannot be fully weaned after the introduction of the blinded solution, the open label dopamine will be replaced by an open label norepinephrine infusion.